Table 1.
Demographics and characteristics at REGAIN baseline of patients who continued from REGAIN into the open-label extension study
| Variable | Eculizumab/eculizumab n = 56 | Placebo/eculizumab n = 61 | All patients N = 117 |
|---|---|---|---|
| Age, yearsa, mean (SD) | 46.8 (15.6) | 47.0 (17.8) | 46.9 (16.7) |
| Sex, n (%) | |||
| Male | 18 (32.1) | 20 (32.8) | 38 (32.5) |
| Female | 38 (67.9) | 41 (67.2) | 79 (67.5) |
| Race, n (%) | |||
| Asian | 3 (5.4) | 16 (26.2) | 19 (16.2) |
| Black or African-American | 0 (0.0) | 2 (3.3) | 2 (1.7) |
| White | 47 (83.9) | 41 (67.2) | 88 (75.2) |
| Other/multiple/unknown | 6 (10.7) | 2 (3.3) | 8 (6.8) |
| Duration of MGb, years, mean (SD) | 10.2 (7.9) | 9.2 (8.6) | 9.7 (8.2) |
| Baseline MG-ADL total score, mean (SD) | 10.3 (3.0) | 9.9 (2.6) | 10.1 (2.8) |
| Baseline MG-QOL15 total score, mean (SD) | 32.5 (12.0) | 30.8 (12.9) | 31.6 (12.5) |
MG myasthenia gravis, MG-ADL myasthenia gravis activities of daily living questionnaire, MG-QOL15 15-item myasthenia gravis quality of life questionnaire, SD standard deviation
aAt first dose in REGAIN
bTime from MG diagnosis to date of first dose in REGAIN